BioDelivery Sciences International, Inc.
https://bdsi.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioDelivery Sciences International, Inc.
Deal Watch: Biogen, AbCellera Team To Find Novel Way To Cross Blood-Brain Barrier
Plus deals involving BiomX/Adapative Phage, One/NEX-I, Shionogi/FunPep, Taiho/Haihe, Kinnate/Pierre Fabre, StemCell Technologies/SQZ and more, as well as tech transfer agreements.
Ozempic Cuts Kidney Risk By 24%
But Novo’s blockbuster lags established drugs in diabetic kidney disease patients, and will probably be regarded as an adjunct.
Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
EU’s Innovative Drug Approval Tally Shows Sharp Decline
The numbers may be down, but Europeans will in future be able to gain access to a number of highly innovative medicines, including several products for hard-to-treat cancers, a gene therapy for severe and moderately severe hemophilia B, and two vaccines against disease caused by respiratory syncytial virus.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Arius Pharmaceuticals
- Arius Two Inc
- Bioral Nutrient Delivery LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice